Dashboard Market News Pricing Contact Us
Search 100,000+ stocks...
English EN
Deutsch DE Español ES 简体中文 中文 हिन्दी HI
Sign Up
Log in
Genome&Company Inc banner
G

Genome&Company Inc
KOSDAQ:314130

Watchlist Manager
Genome&Company Inc
KOSDAQ:314130
Watchlist
Price: 3 905 KRW -2.74% Market Closed
Market Cap: ₩176.7B
Write Note Create Alert Ask AI

Bankruptcy Probability

Genome&Company Inc's probability of bankruptcy is Hidden . The solvency score is Hidden .

We take all the information about a company's solvency, such as how easily it can pay interest on outstanding debt, how much cash it has, the amount of debt, and more, and use it to estimate the probability of bankruptcy.

Probability of Bankruptcy
LOCKED
Unlock

Financial Position

Cash & Short-Term Investments
+
3Y
-40%
5Y
-35%
10Y
-
Long-Term Investments
+
3Y
-
5Y
-
10Y
-
Debt
+
3Y
-54%
5Y
+72%
10Y
-

Solvency Ratios

Solvency Ratios Comparison
Genome&Company Inc Competitors

Country Company Market Cap D/E D/A Interest
Coverage 		Altman
Z-Score 		Quick
Ratio 		Current
Ratio 		Cash
Ratio
KR
Genome&Company Inc
KOSDAQ:314130
176.4B KRW
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
US
AbbVie Inc
NYSE:ABBV
504B USD
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
US
Amgen Inc
NASDAQ:AMGN
242B USD
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
US
Gilead Sciences, Inc
NASDAQ:GILD
195.1B USD
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
135.6B USD
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
84.7B USD
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
US
Moderna Inc
NASDAQ:MRNA
80.8B USD
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
AU
CSL Ltd
ASX:CSL
88.4B AUD
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
US
Natera Inc
NASDAQ:NTRA
57.6B USD
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
NL
argenx SE
XBRU:ARGX
48.9B EUR
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
US
Revolution Medicines Inc
NASDAQ:RVMD
40.2B USD
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
No Stocks Found

Continue Research

Summary
intrinsic value, competitors valuation, and company profile.
DCF Valuation
stock valuation using Discount Cash Flow valuation method.
Relative Valuation
stock valuation using valuation multiples.
Wall St Estimates
price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financial Statements
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financial Statements
Discount Rate
Discover More
Is Genome&Company Inc at risk of bankruptcy?

Genome&Company Inc's probability of bankruptcy is Hidden .

The probability of bankruptcy is estimated using credit risk models that assess financial health, debt levels, interest coverage, and other solvency indicators.

How much debt does Genome&Company Inc have?

As of the latest report, Genome&Company Inc has total debt of 2B KRW. This includes both short-term (0 KRW) and long-term (2B KRW) debt.

You can find a full breakdown on its Balance Sheet.

Back to Top
ALPHA SPREAD
Follow us
Join 362,000+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Valuation Backtest Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.